Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Mar;60(3):547-54.

Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II

Affiliations

Mutations in the COL5A1 gene are causal in the Ehlers-Danlos syndromes I and II

A De Paepe et al. Am J Hum Genet. 1997 Mar.

Abstract

The Ehlers-Danlos syndrome (EDS) is a heterogeneous connective-tissue disorder of which at least nine subtypes are recognized. Considerable clinical overlap exists between the EDS I and II subtypes, suggesting that both are allelic disorders. Recent evidence based on linkage and transgenic mice studies suggest that collagen V is causally involved in human EDS. Collagen V forms heterotypic fibrils with collagen I in many tissues and plays an important role in collagen I fibrillogenesis. We have identified a mutation in COL5A1, the gene encoding the pro(alpha)1(V) collagen chain, segregating with EDS I in a four-generation family. The mutation causes the substitution of the most 5' cysteine residue by a serine within a highly conserved sequence of the pro(alpha)1(V) C-propeptide domain and causes reduction of collagen V by preventing incorporation of the mutant pro(alpha)1(V) chains in the collagen V trimers. In addition, we have detected splicing defects in the COL5A1 gene in a patient with EDS I and in a family with EDS II. These findings confirm the causal role of collagen V in at least a subgroup of EDS I, prove that EDS I and II are allelic conditions, and represent a, so far, unique example of a human collagen disorder caused by substitution of a highly conserved cysteine residue in the C-propeptide domain of a fibrillar collagen.

PubMed Disclaimer

References

    1. Ann Rheum Dis. 1969 May;28(3):228-45 - PubMed
    1. J Cell Sci. 1990 Apr;95 ( Pt 4):649-57 - PubMed
    1. J Invest Dermatol. 1982 Jul;79(1):7-10 - PubMed
    1. J Biol Chem. 1984 Nov 25;259(22):14170-4 - PubMed
    1. Proc Natl Acad Sci U S A. 1985 May;82(10):3385-9 - PubMed

Publication types

MeSH terms